Calidi Biotherapeutics terminated its Standby Equity Purchase Agreement with Yorkville, which allowed for the potential sale of up to $25 million in shares, and reported raising $9.5 million from public offerings and additional funds from warrant exercises and its ATM program, strengthening its cash position.